Clinical Trial Update: Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update assessing olutasidenib for IDH1-mutated acute myeloid leukemia, myelodysplastic syndrome, or chronic myelomonocytic leukemia aft…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• Olutasidenib (olutasidenib)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 | Status: RECRUITING